Drug- and Drug Abuse–Associated Hyperbilirubinemia: Experience With Atazanavir

Jayanta Roy-Chowdhury, Namita Roy-Chowdhury, Irving Listowsky, Allan W. Wolkoff

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Hyperbilirubinemia is a common finding in individuals with a history of substance abuse. Although this may indicate a serious disorder of liver function, this is not always the case. An understanding of bilirubin formation, metabolism, and transport can provide a helpful approach to dealing with these patients. This is typified by studies of patients treated with the antiretroviral drug atazanavir. Atazanavir has been associated with hyperbilirubinemia in as many as one-third of individuals for whom it has been prescribed, evoking concerns of hepatotoxicity. The studies in this report were designed to determine mechanisms by which this occurs. The data show that this drug inhibits the enzyme UDP-glucuronosyl transferase-1A1, responsible for conjugating bilirubin with glucuronic acid. This conjugation step is required for bilirubin excretion into bile, and when it is inhibited, bilirubin refluxes from the liver into the circulation, causing unconjugated hyperbilirubinemia. Other parameters of bilirubin formation, binding to albumin in the circulation, uptake into hepatocytes, and intracellular protein binding in hepatocytes were unaffected by atazanavir. The effect of atazanavir on serum bilirubin levels is reversible, consistent with lack of structural damage to the liver.

Original languageEnglish (US)
Pages (from-to)140-146
Number of pages7
JournalClinical Pharmacology in Drug Development
Volume6
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Hyperbilirubinemia
Bilirubin
Pharmaceutical Preparations
Hepatocytes
Liver Circulation
Glucuronic Acid
Uridine Diphosphate
Liver
Transferases
Protein Binding
Bile
Substance-Related Disorders
Atazanavir Sulfate
Albumins
Enzymes
Serum

Keywords

  • atazanavir
  • drug toxicity
  • hyperbilirubinemia
  • transport
  • UDP-glucuronosyl transferase

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Drug- and Drug Abuse–Associated Hyperbilirubinemia : Experience With Atazanavir. / Roy-Chowdhury, Jayanta; Roy-Chowdhury, Namita; Listowsky, Irving; Wolkoff, Allan W.

In: Clinical Pharmacology in Drug Development, Vol. 6, No. 2, 01.03.2017, p. 140-146.

Research output: Contribution to journalArticle

@article{876ed578cbfb4ff9998f03f311432c36,
title = "Drug- and Drug Abuse–Associated Hyperbilirubinemia: Experience With Atazanavir",
abstract = "Hyperbilirubinemia is a common finding in individuals with a history of substance abuse. Although this may indicate a serious disorder of liver function, this is not always the case. An understanding of bilirubin formation, metabolism, and transport can provide a helpful approach to dealing with these patients. This is typified by studies of patients treated with the antiretroviral drug atazanavir. Atazanavir has been associated with hyperbilirubinemia in as many as one-third of individuals for whom it has been prescribed, evoking concerns of hepatotoxicity. The studies in this report were designed to determine mechanisms by which this occurs. The data show that this drug inhibits the enzyme UDP-glucuronosyl transferase-1A1, responsible for conjugating bilirubin with glucuronic acid. This conjugation step is required for bilirubin excretion into bile, and when it is inhibited, bilirubin refluxes from the liver into the circulation, causing unconjugated hyperbilirubinemia. Other parameters of bilirubin formation, binding to albumin in the circulation, uptake into hepatocytes, and intracellular protein binding in hepatocytes were unaffected by atazanavir. The effect of atazanavir on serum bilirubin levels is reversible, consistent with lack of structural damage to the liver.",
keywords = "atazanavir, drug toxicity, hyperbilirubinemia, transport, UDP-glucuronosyl transferase",
author = "Jayanta Roy-Chowdhury and Namita Roy-Chowdhury and Irving Listowsky and Wolkoff, {Allan W.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1002/cpdd.314",
language = "English (US)",
volume = "6",
pages = "140--146",
journal = "Clinical Pharmacology in Drug Development",
issn = "2160-763X",
publisher = "Sage Periodicals Press",
number = "2",

}

TY - JOUR

T1 - Drug- and Drug Abuse–Associated Hyperbilirubinemia

T2 - Experience With Atazanavir

AU - Roy-Chowdhury, Jayanta

AU - Roy-Chowdhury, Namita

AU - Listowsky, Irving

AU - Wolkoff, Allan W.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Hyperbilirubinemia is a common finding in individuals with a history of substance abuse. Although this may indicate a serious disorder of liver function, this is not always the case. An understanding of bilirubin formation, metabolism, and transport can provide a helpful approach to dealing with these patients. This is typified by studies of patients treated with the antiretroviral drug atazanavir. Atazanavir has been associated with hyperbilirubinemia in as many as one-third of individuals for whom it has been prescribed, evoking concerns of hepatotoxicity. The studies in this report were designed to determine mechanisms by which this occurs. The data show that this drug inhibits the enzyme UDP-glucuronosyl transferase-1A1, responsible for conjugating bilirubin with glucuronic acid. This conjugation step is required for bilirubin excretion into bile, and when it is inhibited, bilirubin refluxes from the liver into the circulation, causing unconjugated hyperbilirubinemia. Other parameters of bilirubin formation, binding to albumin in the circulation, uptake into hepatocytes, and intracellular protein binding in hepatocytes were unaffected by atazanavir. The effect of atazanavir on serum bilirubin levels is reversible, consistent with lack of structural damage to the liver.

AB - Hyperbilirubinemia is a common finding in individuals with a history of substance abuse. Although this may indicate a serious disorder of liver function, this is not always the case. An understanding of bilirubin formation, metabolism, and transport can provide a helpful approach to dealing with these patients. This is typified by studies of patients treated with the antiretroviral drug atazanavir. Atazanavir has been associated with hyperbilirubinemia in as many as one-third of individuals for whom it has been prescribed, evoking concerns of hepatotoxicity. The studies in this report were designed to determine mechanisms by which this occurs. The data show that this drug inhibits the enzyme UDP-glucuronosyl transferase-1A1, responsible for conjugating bilirubin with glucuronic acid. This conjugation step is required for bilirubin excretion into bile, and when it is inhibited, bilirubin refluxes from the liver into the circulation, causing unconjugated hyperbilirubinemia. Other parameters of bilirubin formation, binding to albumin in the circulation, uptake into hepatocytes, and intracellular protein binding in hepatocytes were unaffected by atazanavir. The effect of atazanavir on serum bilirubin levels is reversible, consistent with lack of structural damage to the liver.

KW - atazanavir

KW - drug toxicity

KW - hyperbilirubinemia

KW - transport

KW - UDP-glucuronosyl transferase

UR - http://www.scopus.com/inward/record.url?scp=85014573745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014573745&partnerID=8YFLogxK

U2 - 10.1002/cpdd.314

DO - 10.1002/cpdd.314

M3 - Article

C2 - 28263463

AN - SCOPUS:85014573745

VL - 6

SP - 140

EP - 146

JO - Clinical Pharmacology in Drug Development

JF - Clinical Pharmacology in Drug Development

SN - 2160-763X

IS - 2

ER -